Harrow, Inc. (HROW)
Nasdaq: HROW · Pharmaceutical Preparations · Nashville, TN · filing with the SEC since 2006
Grade5.8
◀ Past 5.8● Present 6.3▶ Future 5.4
Who owns Harrow, Inc.
As filed with the SECHolders of 5% or more
4
Mark L. Baum holds 10.7% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D/A filed Apr 7, 2025 says.
Directors and officers
9
report now, of 19 people on the record since 2012. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Mark L. Baum
SCHEDULE 13D/A · filed Apr 7, 2025 · Common Stock, $0.001 par value per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock
Opaleye Management Inc.
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock, $0.001 par value per share · 7.61% in May 11, 2026
Daniel Kaufman
SCHEDULE 13G · filed Mar 11, 2026 · Common Stock, $0.001 par value per share
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What HROW reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Santen Products Acquisition
A company bought · acquisition · owns, named in the 10-K filed Mar 2, 2026
Vevye
A company bought · acquisition · owns, named in the 10-K filed Mar 2, 2026
7 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 2, 2026.
Insider tradesForm 4
1sales
4purchases
0sales on a scheduled plan
1people selling
$500,000sold, in dollars
$500,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 22 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% owner | 6 | $9.2M | 0 | 0 | $0 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER | 1 | $500,000 | 0 | 0 | $0 |
| Baum Mark L | CHIEF EXECUTIVE OFFICER | 0 | $0 | 0 | 1 | $300,000 |
| Boll Andrew R. | PRESIDENT AND CFO | 0 | $0 | 0 | 1 | $100,000 |
| Graves Adrienne L | director | 0 | $0 | 0 | 1 | $0 |
| Silvernail Lauren P | director | 0 | $0 | 0 | 1 | $0 |